A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma

European Urology

Volumn 62, Issue 6, 2012, Pages 1013-1019

  Tannir, Nizar M ^a   Plimack, Elizabeth ^b   Ng, Chaan ^a   Tamboli, Pheroze ^a   Bekele, Nebiyou B ^a   Xiao, Lianchun ^a   Smith, Lisa ^a   Lim, Zita ^a   Pagliaro, Lance ^a   Araujo, John ^a   Aparicio, Ana ^a   Matin, Surena ^a   Wood, Christopher G ^a   Jonasch, Eric ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Chromophobe renal cell carcinoma; Non clear cell renal cell carcinoma; Papillary renal cell carcinoma; Renal cell carcinoma variant histology; Sunitinib; Targeted therapy

Indexed keywords

SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; CANCER PATIENT; CANCER SURVIVAL; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DYSPHAGIA; DYSPNEA; EMBOLISM; FAINTNESS; FEBRILE NEUTROPENIA; FEMALE; HEART INFARCTION; HEMOLYSIS; HISTOLOGY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPOGLYCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LETHARGY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDULLARY CARCINOMA; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; NON CLEAR CELL RENAL CELL CARCINOMA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SARCOMATOID CARCINOMA; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRROLES; YOUNG ADULT;

EID: 84868532639     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.06.043     Document Type: Article

References (30)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA: Cancer J Clin 62 2012 10 29
2. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
3. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
4. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
5. B. Escudier, A. Pluzanska, and P. Koralewski Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
6. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
7. B.I. Rini, S. Halabi, and J.E. Rosenberg Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
8. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
9. B.I. Rini, B. Escudier, and P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
10. T.K. Choueiri, A. Plantade, and P. Elson Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma J Clin Oncol 26 2008 127 131
11. M.E. Gore, C. Szczylik, and C. Porta Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol 10 2009 757 763
12. D.Y. Heng, W. Xie, and M.M. Regan Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
13. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
14. A. Ravaud, S. Oudard, and G. Gravis-Mescam First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP) [abstract 5146] J Clin Oncol 27 2009 15s
15. A.M. Molina, D.R. Feldman, and M.S. Ginsberg Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma Invest New Drugs 30 2012 335 340
16. J.L. Lee, J.-H. Ahm, and H.Y. Lim Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma Ann Oncol 23 2012 2108 2114
17. M. Jeffers, L. Schmidt, and N. Nakaigawa Activating mutations for the met tyrosine kinase receptor in human cancer Proc Natl Acad Sci U S A 94 1997 11445 11450
18. L. Schmidt, F.M. Duh, and F. Chen Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nat Genet 16 1997 68 73
19. L. Schmidt, K. Junker, and N. Nakaigawa Novel mutations of the MET proto-oncogene in papillary renal carcinomas Oncogene 18 1999 2343 2350
20. P. Sweeney, A.K. El-Naggar, S.H. Lin, and L.L. Pisters Biological significance of c-met over expression in papillary renal cell carcinoma J Urol 168 2002 51 55
21. J.P. Dutcher, P. de Souza, and D. McDermott Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies Med Oncol 26 2009 202 209
22. M.S. Gordon, M. Hussey, and R.B. Nagle Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317 J Clin Oncol 27 2009 5788 5793
23. M.B. Amin, G.P. Paner, and I. Alvarado-Cabrero Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases Am J Surg Pathol 32 2008 1822 1834
24. L. Huo, J. Sugimura, and M.S. Tretiakova C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas Hum Pathol 36 2005 262 268
25. C.D. Blanke, G.D. Demetri, and M. von Mehren Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT J Clin Oncol 26 2008 620 625
26. D.M. Nanus, A. Garino, M.I. Milowsky, M. Larkin, and J.P. Dutcher Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma Cancer 101 2004 1545 1551
27. N. Haas, X. Lin, and J. Manola A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 Med Oncol 29 2012 761 767
28. J.P. Dutcher, and D. Nanus Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy Med Oncol 28 2011 1530 1533
29. A.R. Golshayan, S. George, and D.Y. Heng Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy J Clin Oncol 27 2009 235 241
30. A.M. Molina, S.K. Tickoo, and N. Ishill Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease Am J Clin Oncol 34 2011 454 459